Journal of Vaccines & Vaccination

A novel therapy for melanoma developed in mice: Transformation of melanoma into dendritic cells with Listeria monocytogenes

9^th Global Summit and Expo on Vaccines & Vaccination

November 30-December 02, 2015 San Francisco, USA

Carmen Alvarez-Dominguez1, Lucia Bronchalo-Vicente1,2, Javier Freire2, Jose Javier Gomez-Roman2 and Sonsoles Yañez-Diaz2

1Instituto de Investigacion Marques de Valdecilla, Spain 2Universitario Marqués de Valdecilla, Spain

Posters-Accepted Abstracts: J Vaccines & Vaccin

Abstract:

Listeria monocytogenes is a gram-positive bacteria and human pathogen widely used in cancer immunotherapy because of its capacity to induce a specific cytotoxic T-cell response in tumours. This bacterial pathogen strongly induces innate and specific immunity with the potential to overcome tumour induced tolerance and weak immunogenicity. Here, we propose a Listeria based vaccination for melanoma based on its tropism for these tumour cells and its ability to transform in vitro and in vivo melanoma cells into matured and activated dendritic cells with competent microbicidal and antigen processing abilities. This Listeria based vaccination using low doses of the pathogen caused melanoma regression by apoptosis as well as bacterial clearance. Vaccination efficacy is LLO dependent and implies the reduction of LLO-specific CD4+ T cell responses, strong stimulation of innate pro-inflammatory immune cells and a prevalence of LLO-specific CD8+ T cells involved in tumour regression and Listeria elimination. These results support the use of low doses of pathogenic Listeria as safe melanoma therapeutic vaccines that do not require antibiotics for bacterial removal.

Biography :

Email: calvarez@humv.es